PitchSend

Investor Presentaiton

A focused global biopharma company with bold ambitions GSK Strategy focused on the prevention and treatment of disease World leader in infectious disease based on science of the immune system Highly attractive medium-term' target for sales and adjusted operating profit CAGR² Confident in ability to sustain growth through the decade and beyond 1. Medium-term is 2021-2026, excluding COVID-19 solutions 2. At constant exchange rates (CER) GSK 28

View entire presentation